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The aim of this study was to describe the fate of patients with newly diagnosed acute myeloid leukemia (AML)
who did not achieve an initial remission while being treated on a contemporary cooperative group trial. We
analyzed the outcome of patients entered into S0106, a recently reported cooperative group trial for patients
with newly diagnosed AML. A total of 589 eligible patients was treated, of whom 150 (25%) did not achieve a
remissionwhile on study andwere available for further analysis. The 4-year survival rate for the entire cohort of
150 patients was 23%. Among the 64 patients who received an allogeneic hematopoietic cell transplant, the 4-
year survival rate was 48% compared with 4% for the 86 patients who did not undergo transplantation. Among
those transplanted, we could not detect a difference in outcome according to remission status, donor source,
type of preparative regimen, or cytogenetic risk category. More than 20% of patients with newly diagnosed AML
who fail induction therapy can still be cured, particularly if they are able to receive an allogeneic hematopoietic
cell transplant. These results suggest that early HLA typing and donor identiﬁcation are important components
of the initial therapy of AML.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Based on results of contemporary cooperative group
studies, approximately 70% to 75% of younger patients
(age<65years)with newly diagnosed acutemyeloid leukemia
(AML) will achieve complete remission (CR) if treated with
standard induction therapy [1,2]. The treatment-relateddgments on page 564.
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14.10.025mortality associatedwith induction therapy has fallen to 5% or
less [3]. Thus, a sizable proportion of patients, perhaps 20% to
25%,will survive induction therapybutnot achievean initial CR
with protocol-directed therapy. The fate of such patients is not
well described, particularly in the current era where the
spectrumof subsequent therapies available topatientswho fail
induction has expanded, especially with the broader avail-
ability of hematopoietic cell transplantation (HCT). We hy-
pothesize that knowledge of the outcome of subsequent
therapies in patients who fail induction might be useful in
developing further clinical studies and treatment recommen-
dations. Accordingly, we followed up on all patients who
failed to achieve a CRon a recently reported cooperative group
trial.
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S0106 Patient Population
S0106 (clinicaltrials.gov identiﬁer: NCT00085709) is a recently reported
study testing the efﬁcacy of the addition of gemtuzumab ozogamicin to
conventional AML therapy. The patient population, study design, and
treatment groups have been reported [1]. Brieﬂy, patients with de novo
AML, aged 18 to 60 years, with a Zubrod performance score of 0 to 3 and
adequate organ function were eligible. All patients provided written
informed consent in accordance with local policies, federal regulations, and
the Declaration of Helsinki.
S0106 Study Design
At registration, patients were randomly assigned 1:1 to receive
either daunorubicin 45 mg/m2 by i.v. push on days 1 through 3, cytarabine
100mg/m2bycontinuous i.v. infusions ondays 1 through7, and gemtuzumab
ozogamicin 6mg/m2 by 2-hour i.v. infusion on day 4 or daunorubicin 60mg/
m2 by i.v. push on days 1 through 3 and cytarabine 100mg/m2 by continuous
i.v. infusions on days 1 through 7. Marrow response was assessed on day 14.
For both groups, a second course of induction using daunorubicin was rec-
ommended for patients with marrows having more than 20% cellularity and
more than 5% blasts at day 14. If the day 14 marrowwas hypocellular, repeat
marrows were suggested until cellularity returned to greater than 20% and
either a CR was documented or greater than 5% blasts were seen, at which
point repeat treatment with daunorubicin was recommended.
Patients who achieved a CR were eligible to receive 3 courses of
consolidation therapy with cytarabine 3 g/m2 by 3-hour continuous i.v.
infusions every 12 hours on days 1, 3, and 5. Consolidation courses were
administered monthly. After completing consolidation therapy, patients
were eligible for postconsolidation randomization (1:1) between gemtu-
zumab ozogamicin (5 mg/m2, 3 doses at least 28 days apart) or observation.
Induction Failure Patient Cohort
The S0106 patients included in and excluded from this analysis are
summarized in Figure 1. Of 637 patients registered to S0106, 595 patients
were eligible, 589 received protocol therapy, and 425 achieved a CR (71%). Of
the 164 eligible patients who received protocol therapy but did not achieve aFigure 1. Flowchart of S0106 patieCR,14 were excluded from further analysis because they were lost to follow-
up, withdrew consent for the study, or went off protocol therapy to receive
therapy for biphenotypic leukemia. Therefore, 150 patients are included in
the following analysis.
Statistical Methods
Date of induction failure was deﬁned as date taken off protocol therapy
because of death or documented induction failure. Survival after induction
failurewasmeasured from date of induction failure to death from any cause,
with patients last known to be alive censored at the date of last contact.
Survival after transplant was deﬁned from the date of transplant to death
from any cause, with patients last known to be alive censored at the date of
last contact. Patient characteristics were tabulated and summarized. Sur-
vival was estimated using the Kaplan-Meier method. Log-rank tests were
used to compare survival curves.
RESULTS
Patient Characteristics
The characteristics of the 150 patients who failed induc-
tion are summarized in Table 1. The median age was 48 years
(range, 18 to 60), 49% were women, and 84% had a perfor-
mance score of 0 or 1. Cytogenetic analysis was available
for 116 patients (68%); 34 patients did not have specimens
submitted for central review. Of those with centrally
reviewed cytogenetics, 7% were favorable, 47% were inter-
mediate, 43% were unfavorable, and 3% were clonal but
unclassiﬁed according to the SWOG classiﬁcation schema [4].
FLT3-ITD and NMP1 mutational status was available for 73
patients. Among patients with molecular data, 3% were
NMP1 mutated but FLT3-ITD wild-type and 30% were FLT3
mutated. Median time between registration and date of
induction failure was 27 days (range, 2 to 138).nts included in the analysis.
Table 1
Patient Characteristics (N ¼ 150)
Characteristic Value
Median age, yr (range) 48 (18-60)
Sex
Female 73 (49)
Male 77 (51)
Performance score
0 52 (35)
1 73 (49)
2 14 (9)
3 10 (7)
Missing 1
FAB
M0 16 (11)
M1 34 (23)
M2 39 (27)
M4 35 (24)
M4EOS 2 (1)
M5 13 (9)
M6 5 (3)
M7 2 (1)
Missing 4
Cytogenetic risk
Favorable 7 (6)
Intermediate 55 (47)
Unknown risk 4 (3)
Unfavorable 50 (43)
Not done 34
NPM1/FLT3-ITD
NPM1þ/FLT3-ITDþ 7 (10)
NPM1þ/FLT3-ITD 2 (3)
NPM1/FLT3-ITDþ 15 (21)
NPM1/FLT3-ITD 49 (67)
Not done 77
Values are number of case with percents in parentheses, unless otherwise
noted.
Figure 2. Flowchart of S0106 patients who failed induction after protocol
therapy.
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Table 2. Seventeen patients died after induction therapy
without ever having a marrow exam, and 3 patients were
removed from protocol therapy without a bone marrow
exam. Of the 130 patients who had at least 1 marrow exam
after induction, 25 patients achieved a complete response
with incomplete count recovery (CRi), 6 were classiﬁed as a
partial remission, and 99 were classiﬁed as having resistant
disease. Excluding 19 patients who died within 28 days of
registration to the study, 85 patients were taken off S0106
and declared induction failures after receiving 1 cycle of
therapy, including 14with a CRi. Sixty patients were taken off
study after failing a second cycle of induction.Clinical Course after Induction Failure
Figure 2 illustrates the course of patients after failure of
induction on S0106. Thirty-six patients, including the 19 who
died within 28 days of study registration, received no further
therapy. Among the 114 patients who are known to have
received further therapy, 112 received some form of
chemotherapy and 2 were transplanted without furtherTable 2
Primary Induction Failure Summary (N ¼ 150)
Reason n (%)
Died without bone marrow exam 17 (11%)
Off protocol without bone marrow exam 3 (2%)
CRi 25 (17%)
Partial remission 6 (4%)
Resistant disease 99 (66%)treatment. Most patients treated with chemotherapy
received at least 1 cycle that included some form of high-
dose cytarabine (1.5 to 3.0 g/m2/day for 2 to 6 days)
(HDAC) (84/112, 75%). Overall, 53% of patients who received
reinduction or salvage therapy achieved a CR. Of the 60
patients who obtained a CR, 50 (83%) received some form of
HDAC. Among patients who received reinduction or salvage
therapy, 62 (56%) went on to receive a transplant, and among
these 62 patients, 50 (81%) received HDAC. Among the 46
patients who achieved CR andwent on to transplant, 32were
in CR at the time of transplant and CR status at time of
transplant was not known for 4 patients. Among the 46
patients who achieved CR and went on to transplant, 40
(87%) received some form of HDAC.
The 4-year survival rate for the entire cohort of 150 pa-
tients with primary induction failure was 23% (95% conﬁ-
dence interval,17% to31%) (Figure3). The4-year survival rates
after primary induction failure for patients who received a
transplant was 48% and for thosewhowere not transplanted,
4% (Figure 4). In an attempt to account for the lead time bias
associated with patients needing to live long enough to
receive a transplant, we also performed a landmark survivalFigure 3. Survival of full induction failure cohort.
Figure 4. Survival after failure stratiﬁed by transplant.
M. Othus et al. / Biol Blood Marrow Transplant 21 (2015) 559e574562analysis restricted to patients alive 90 days after induction
failure. As shown, 4-year survival rates from day 90were 49%
for those transplanted versus 8% for those not transplanted.
Among the entire cohort of 150 patients, those with unfa-
vorable cytogenetics had signiﬁcantlyworse survival than the
favorable (P ¼ .020), intermediate (P ¼ .002), and not done
(P ¼ .001) groups. There were no signiﬁcant differences
among the NPM1/FLT3 cohorts.Figure 5. Survival after transplant stratiﬁed by CR at time of transplant (yes vers
(myeloablative versus reduced intensity), and cytogenetic risk (intermediate versus uWhen comparing survival after transplant by CR at time
of transplant (yes versus no), type of donor (matched related
versus other), transplant conditioning regimen (ablative
versus reduced intensity), and cytogenetic risk category
(intermediate versus unfavorable), there were no signiﬁcant
differences. However, there was a trend toward improved
long-term survival in patients who were in CR at the time of
transplant (P ¼ .13, Figure 5).us no), donor (matched related versus not), conditioning regimen intensity
nfavorable).
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The results of this analysis demonstrate that a substantial
proportion (over 20%) of patients who were determined
to have failed primary induction therapy for AML on a
contemporary cooperative group trial became long-term
survivors. Even after attempting to account for the lead
time bias associated with having to live long enough to be
transplanted, the likelihood of long-term survival appeared
to be signiﬁcantly higher (49%) if patients were transplanted
than if they were not (8%). These results suggest that early
HLA typing and donor identiﬁcation are important compo-
nents of the initial therapy of AML.
In reviewing the results of this study, a number of topics
deserve discussion. First is the issue of the deﬁnition of pri-
mary induction failure. The deﬁnition of resistant disease
adopted by the International Working Group and used by the
European LeukemiaNet requires the patient to be alive for 7
or more days after the completion of the ﬁrst course of
chemotherapy and to have persistent leukemia cells in the
peripheral blood or bone marrow at that time [5,6]. Primary
induction failure then combines those patients who die early
and those with resistant disease. Other studies use alterna-
tive deﬁnitions, most commonly deﬁning patients as having
primary induction failure if they die early or fail to achieve a
CR after 2 cycles of standard-dose cytarabine and daunoru-
bicin therapy or 1 cycle of an HDAC containing regimen. As
reviewed by Ravandi [7], there is no single widely accepted
deﬁnition of primary induction failure. In this report, we
used the pragmatic deﬁnition of not achieving a CR while on
protocol therapy.
In the S0106 protocol, patients were treated with an
initial cycle of induction therapy and a bone marrow was
mandated 14 days after the start of therapy. If on day 14
marrow >5% blasts were seen and cellularity was >20%, a
second induction course using standard-dose daunorubicin
and cytarabine was recommended. If cellularity was <20%,
repeat marrows were suggested until patients either entered
remission or >5% blasts with >20% cellularity was seen, at
which time a second induction cycle could be initiated.
Despite this recommendation, a substantial number of
patients were removed from S0106 after receiving only 1
induction cycle. Most of these patients subsequently were
treated with HDAC-containing regimens.
Data were not collected to explain why physicians
removed patients from study after a single cycle of induction,
but it is reasonable to assume treating physicians believed
patients would be better served if treated with an HDAC-
containing regimen. This experience is not unique to
S0106; similar behavior was seen in a recently reported
ECOG trial [2] where over 50% of those failing the ﬁrst cycle
of induction were removed from study instead of receiving a
second cycle of therapy (M. Tallman, March 1, 2014, personal
communication). No data are available to prove or disprove
that switching from a second cycle of standard induction to
an alternative therapy is of beneﬁt, but a study formally
testing this would be of great interest.
In the S0106 study,118 patients who failed to achieve a CR
with their ﬁrst cycle of therapy were treated with a second
cycle of standard induction therapy on study and 49% ach-
ieved a CR. Among the 69 patients who were removed from
study after 1 cycle and treated with alternative regimens,
57% eventually got a CR. It might be mentioned that the 49%
CR rate on study was with a single second cycle, whereas the
57% off study includes patients who may have achieved CR
after second, third, or subsequent salvage cycles. The onlydifference we were able to uncover between those receiving
a second cycle on protocol versus those taken off was a
greater likelihood for those being treated at SWOG member
(academic) sites to be removed from study. Whether this
reﬂects the availability of more alternative therapeutic
options or studies at academic sites or some other bias is
unknown. Greater understanding of who is likely to beneﬁt
or not from a second cycle of conventional induction versus
those for whom an alternative therapy is a better choice
would be of great practical importance. Until such facts are
known, clinical trials would be more interpretable if there
were increased uniformity in treatment approaches. The
removal of a substantial proportion of patients after a single
cycle of induction artiﬁcially lowers the CR rate with that
approach, making comparisons across studies difﬁcult, and if
the practice is not applied equivalently in both arms of a
randomized trial, such behavior could potentially bias the
results of such studies.
The fact that HCT can cure some patients who never
achieve an initial remissionwith conventional chemotherapy
has been documented several times. Reports from both sin-
gle institutions and registry data suggest that approximately
20% to 25% of patients transplanted from matched siblings
for primary refractory AML can become long-term disease-
free survivors [8-10]. More recently, similar results have been
reported in recipients of unrelated donor transplants for
primary induction failure [11]. Transplantation requires
donor identiﬁcation, insurance clearance, and referral to a
transplant center, which can be formidable barriers to an
urgent transplant for patients with primary induction failure.
Thus, it is difﬁcult to gauge how highly selected the trans-
planted patients were in these previous reports.
S0106 contained no speciﬁc instructions about how to
handle patients with primary induction failure. Nonetheless,
fully 43% of those who failed primary induction were able to
undergo transplantation. If the analysis were restricted to
those who lived at least 90 days after failure and thus pre-
sumably would have had enough time for a donor to be
identiﬁed and to initiate the transplant process, 60% were
actually transplanted. We do not have data about why the
other 40% were not transplanted or how the 40% may have
differed from those who were transplanted. The 60% rate of
transplantation was somewhat unexpected. Several factors
probably account for this high rate of transplantation. First,
there has been impressive expansion of alternative donor
availability in the form of unrelated donors and cord blood
banks. Second, many institutions participating in S0106 have
large, active transplant programs. This high rate of trans-
plantation for patients with primary induction failure is not
typical of practice across the United States. According to
Surveillance, Epidemiology, and End Results statistics, there
were approximately 6890 new cases of AML in patients aged
<66 last year, and assuming a CR rate of 70%, there should
have been 2067 patients failing induction [12]. According to
the Center for International Blood and Marrow Transplant
Research, only 316 transplants were conducted in the United
States last year for patients with primary refractory AML [13].
This suggests that a procedure with a curative potential was
not made available to a large number of patients. Further
research into the reasons for the restricted access to trans-
plantation in this patient population would be of interest.
Among those who were transplanted, 48% were alive
more than 4 years later. This proportion is higher than that
previously reported for patients transplanted after primary
induction failure. This difference may be due, at least in
M. Othus et al. / Biol Blood Marrow Transplant 21 (2015) 559e574564part, to improvements in allogeneic HCT technologies and
supportive care measures over the last 2 decades, as docu-
mented in numerous reports [14-18]. Part of the difference
may also be due to differences in the patient population.
Some previous reports deﬁned their patient population
as those who “had never achieved a ﬁrst CR with che-
motherapy” without regard to the number of cycles of
induction.
In the current study, 2 patients went directly to transplant
after failing 1 cycle of induction, and 1 of these patients is
alive in remission more than 2 years after the transplant.
Other previous reports were restricted to those patients who
had failed to achieve a CR after 2 or more courses of induc-
tion. Most of these studies do not deﬁne what proportion, if
any, of the patients achieved a remission with alternative
therapy before transplant. In the current study, 21 patients
had failed 2 cycles of protocol induction and went on to get a
transplant, and of these, the 4-year survival rate after
transplant was 37%. Our best results were seen in the subset
of patients who failed to achieve a CR on study but managed
to achieve a CR with alternative therapy before transplant.
Their outcomes were essentially the same as reported for
patients transplanted in ﬁrst remissionwith a 4-year survival
after transplant of 56%. Among those transplanted with
active disease, the 4-year survival was 30%, a proportion very
similar to that reported in other studies of transplantation for
primary refractory AML. We could not detect an impact of
donor source (related versus unrelated), intensity of pre-
parative regimen (myeloablative versus reduced intensity),
or cytogenetic risk category (intermediate versus unfavor-
able) on outcome. However, the small number of patients
and nonrandomized nature of the study limit the interpret-
ability of these results.
In summary, over 20% of patients who failed to achieve a
CR on a contemporary cooperative group trial became long-
term survivors, largely because of the availability of alloge-
neic HCT. This result underscores the potential importance of
early HLA typing, donor search, and referral to a transplant
center. Our experience also highlights a number of unsettled
issues. Is there a population of patients, such as those who
achieve a CRi, who should go straight to transplant after
failing their initial cycle of induction therapy? Can we iden-
tify those patients who, even though they fail the ﬁrst round
of standard induction, are likely to achieve a CR with a sec-
ond cycle? Does switching to an alternative chemotherapy
after failing a ﬁrst cycle beneﬁt selected patients? Answers to
these questions should improve cure rates in AML.ACKNOWLEDGMENTS
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